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Abstract
Background: Mice carrying the spontaneous genetic mutation known as Wallerian degeneration
slow (Wlds) have a unique neuroprotective phenotype, where axonal and synaptic compartments
of neurons are protected from degeneration following a wide variety of physical, toxic and
inherited disease-inducing stimuli. This remarkable phenotype has been shown to delay onset and
progression in several mouse models of neurodegenerative disease, suggesting that Wlds-mediated
neuroprotection may assist in the identification of novel therapeutic targets. As a result, cross-
breeding of Wlds mice with mouse models of neurodegenerative diseases is used increasingly to
understand the roles of axon and synapse degeneration in disease. However, the phenotype shows
strong gene-dose dependence so it is important to distinguish offspring that are homozygous or
heterozygous for the mutation. Since the Wlds mutation comprises a triplication of a region already
present in the mouse genome, the most stringent way to quantify the number of mutant Wlds alleles
is using copy number. Current approaches to genotype Wlds mice are based on either Southern
blots or pulsed field gel electrophoresis, neither of which are as rapid or efficient as quantitative
PCR (QPCR).
Results: We have developed a rapid, robust and efficient genotyping method for Wlds using QPCR.
This approach differentiates, based on copy number, homozygous and heterozygous Wlds mice
from wild-type mice and each other. We show that this approach can be used to genotype mice
carrying the spontaneous Wlds mutation as well as animals expressing the Wlds transgene.
Conclusion: We have developed a QPCR genotyping method that permits rapid and effective
genotyping of Wlds copy number. This technique will be of particular benefit in studies where Wlds
mice are cross-bred with other mouse models of neurodegenerative disease in order to
understand the neuroprotective processes conferred by the Wlds mutation.
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Background
The Wallerian degeneration slow gene (Wlds) protects
axons and synapses in both the CNS and PNS from injury-
, neurotoxin- and inherited neurodegenerative conditions
[1-5]. These properties have been shown to mitigate dis-
ease progression in several mouse models of neurodegen-
erative disease, including certain forms of motor neuron
disease [[6,7]; but see [8]], gracile axonal dystrophy [9],
Parkinson's disease [10], transient global cerebral
ischemia [11], and myelin-related axonopathies [12].
Moreover, this remarkable neuroprotective phenotype has
been transferred to other species, including rats and Dro-
sophila [13,14]. The ability to deliver the Wlds gene to wild-
type cells and confer neuroprotection across different spe-
cies offers the possibility of developing Wlds-based thera-
peutics for treating human disease [5,13,15-17].
Evidence from studies of natural mutant mice and mice
transgenic for WldS suggests that its neuroprotective effect
is strongly gene-dose dependent. For instance, reducing
WldS protein expression by 50% removes almost all of the
protective effect on motor nerve terminals while further
reductions in the expression level additionally weakens
the protection of distal axons (3, 18). As cross-breeding of
Wlds mice with other mouse models of neurodegenerative
disease becomes more commonplace, the ability to iden-
tify and distinguish wild-type from heterozygous and
homozygous mice becomes more critical.
The WldS mutation is a triplication of a region already
present in the wild-type animal, encoding a fusion protein
comprising the full length of nicotinamide mononucle-
otide adenylyltransferase 1 (Nmnat1; a NAD+ synthesiz-
ing enzyme) coupled by a unique 18-amino acid
sequence to the N-terminal 70 residues of the ubiquitina-
tion enzyme Ube4b [18,19]. Therefore, the means availa-
ble to assess the number of mutant WldS alleles present are
by using either, the strength of the neuroprotective pheno-
type (for instance, based on protection of axons and syn-
apses following a surgical nerve lesion) or detecting the
copy number of the mutation. As well as an inefficient use
of resources, the first approach is not suitable for genotyp-
ing on ethical and temporal grounds: an invasive proce-
dure (nerve injury or biopsy) is required to test for
strength of neuroprotection over a period of several days
and provides only an indirect and semi-quantitative
measure. The second approach is therefore the only one
suitable for exact genotyping purposes.
Initially, attempts to PCR across the chimeric boundary
were unreliable due to the very high GC content at that
point in the sequence [20]. Some success was found
through the use of Southern blots in identifying
homozygous animals from heterozygous animals as it can
be used to some extent to distinguish the genotype by
band intensity [20]. However, Southern blotting proved
to be an inefficient method for this type of genotyping as
the results were often influenced by the need for equiva-
lent loading concentrations, inconsistent DNA digestions,
problems with blotting efficiency, and other factors that
affected the quantifiable intensity of blots, their signal-
noise ratio and the ability of the researcher to distinguish
between samples on a film. A more robust method for
genotyping WldS mice was also reported by Mi and col-
leagues [20] based on Pulsed Field Gel Electrophoresis
(PFGE). The PFGE method is based on fragment size
rather than band intensity. Problems with this approach
include the requirement for post-mortem material (not
ideal for cross-breeding programs), time taken to obtain
data and the requirement for the use of radio-labelled
probes.
Here we report the development of a novel QPCR geno-
typing method that will allow rapid and effective genotyp-
ing of Wlds copy number.
Results and discussion
Quantitative PCR (QPCR) on genomic DNA for 
genotyping Wlds mice
C57BL/6J and C57BL/Wlds mice were obtained from Har-
lan UK and, where required were cross-bred to obtain F1
mice, heterozygous for Wlds. Ear punches were taken
from mice between 1 and 4 months of age (N = 36 of con-
firmed genotype, N = 91 of unknown genotype). Tail tips
were taken from transgenic rat lines Tg23 (N = 10) and
Tg79 (N = 14). The investigator carrying out the QPCR
screen was always blinded to the genotype of each tissue
sample.
Genomic DNA was extracted using a modified proteinase
K digestion/isopropanol precipitation protocol [21]. Tis-
sue was incubated in tail lysis buffer (100 mM Tris-HCl,
pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 100 µg/
ml Proteinase K). Samples were incubated overnight at
55°C. Lysed tissue was vortexed for 1 minute and spun at
15800 g for 10 minutes to remove hair and bone. The
supernatant was decanted into a new tube and isopropa-
nol was added (equal volume to the tail lysis buffer used
earlier). The solutions were inverted until a white precipi-
tate was seen. The solution was centrifuged and the pel-
leted DNA was washed with 70% ethanol and air dried
before it was resuspended in an appropriate volume of 1
× TE buffer. For example, a 5 mm length of tail tip was
digested and the DNA was finally resuspended in 50 µl of
TE buffer and then stored at -20°C as a stock solution.
The primers and probes (TaqMan Probes) were designed
using Primer Express software as described in the ABI
Primer Express User Bulletin (P/N 4317594). Wlds prim-
ers were based on Genbank entry AF260927 and recogniseMolecular Neurodegeneration 2007, 2:21 http://www.molecularneurodegeneration.com/content/2/1/21
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and amplify bases 810–885 of the Wlds chimeric gene
(Figure 1). The Wlds probe was tagged with a FAM fluoro-
phore and a TAMRA quencher. The product of the Wlds
reaction is a 75 bp amplicon. β-Tubulin primers were
based on Genbank entry M28739. The probe was tagged
with a VIC fluorophore and a TAMRA quencher. The prod-
uct of the β-Tubulin reaction is an 81 bp amplicon. The
sequences (5'-3') used were as follows:
Wlds forward GGCAGTGACGCTCAGAAATTC
Wlds reverse GTTCACCAGGTGGATGTTGCT
Wlds probe TCTACGAGTCCGATGTGCTGTGGAGACA
β-Tubulin forward GCCAGAGTGGTGCAGGAAATA
β-Tubulin reverse TCACCACGTCCAGGACAGAGT
β-Tubulin probe CTCGGCAAAGGGCCACTACACA-
GAGG
A serial dilution of genomic DNA from wild-type C57Bl/
6J mice was used as a template for PCR to test the effi-
ciency of amplification of the two primer pairs. The
genomic DNA was diluted 1 in 10 each time and correla-
tion coefficients were obtained for each primer pair (Fig-
ure 2). PCR efficiency was calculated by plotting the
Threshold cycle (Ct) as a function of Log10 concentration
of the template used (Figure 2; x-axis plotted as -Log µg
DNA. See Applied Biosystems website for user bulletin #2
[22]). The slope of the trend line produced is a function of
PCR efficiency, with a slope of -3.32 indicating close to
100% efficiency [22]. Standard curves suggested efficient
amplification of both primer sets, as indicated by correla-
tion coefficients and linear regression slopes. Primers
against a region of Wlds and β-tubulin  gave correlation
coefficients of 0.9989 and 0.9928 respectively, with slopes
of -3.455 for β-tubulin and -3.3647 for Wlds (Figure 2). The
reactions were found to proceed similarly when primers
were used both separately and together, indicating that
the two separate primer pairs do not interact with each
other. Once this had been demonstrated, genotyping reac-
tions were reliably performed containing both sets of
primers and probes in the same well.
The optimal primer concentrations used were 900 nM and
the optimal probe concentration was found to be 250 nM.
The PCR mix (TaqMan universal PCR master mix, no
amperase UNG from ABI part # 4364341) was prepared
according to the manufacturer's instructions. 1 µl of DNA
was used at a concentration of 1:200 dilution (in TE
buffer) of the original stock sample for each reaction. All
reactions were carried out in triplicate on an ABI Prism
7000 sequence detection system using Applied Biosys-
tems' standard thermal cycling parameters.
Primers for Wlds and β-tubulin have very similar R2 values Figure 2
Primers for Wlds and β-tubulin have very similar R2 
values. Standard curves for the Wlds and β-tubulin gene in a 
serially diluted (1 in 10) template genomic DNA sample from 
wild-type (C57Bl/6J). Efficient amplification was obtained for 
both sets of primers, as demonstrated by the slopes of linear 
regression of the standard curves, and good correlation coef-
ficients. Ct is cycle threshold.
The Wlds mutation and transgene Figure 1
The Wlds mutation and transgene. The spontaneous 
mutation discovered in the Wlds mouse and the transgene 
used to make the various transgenic Wlds animals including 
Tg4836 mouse, Tg23 and Tg79 rat lines. The triplication 
results in the Wlds mouse having one full copy of Nmnat1 
(shown in orange) and Ube4b (shown in brown) at either 
ends if the triplicated region. Within the triplicated region 
are 2 copies of an in frame fusion of the N70 amino acids of 
Ube4b linked to the whole coding region of Nmnat1 leading 
to the expression of 18 amino acids which are normally con-
tained within the 5' untranslated region of Nmnat1 (termed 
Wld-18 shown in red) which has been used for antibody tar-
geting. Primers against the Wlds sequence were designed to 
amplify bases 810–885 in the Genbank sequence AF260927 
that correspond to a portion of the Nmnat-1 sequence in the 
chimeric Wlds product. Arrows indicate approximate site of 
amplification on the gene schematic. Figure modified from 
Gillingwater et al., 2006 [17].Molecular Neurodegeneration 2007, 2:21 http://www.molecularneurodegeneration.com/content/2/1/21
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The product of a PCR for the Wlds amplicon alone run on
an ethidium bromide stained gel showed that bands from
each genotype could not be distinguished from each other
(data not shown). However, the 2-∆∆CT method (for more
detail see Applied Biosystems website for user bulletin
#2), using β-tubulin as an endogenous control and Wlds as
a calibrator, allowed determination of copy number.
Amplification plots for wild-type, heterozygous-Wlds and
homozygous-Wlds showed clear differences for the ∆CT
between each group (Figure 3 &4). The difference between
β-tubulin and Wlds amplicon product at the set threshold
can be used to determine Wlds genotype. A wild-type
mouse gives a mean cycle difference of -0.40 (± 0.26 SD)
with 95% confidence limits of -1.04 & +0.24. A mouse
heterozygous for Wlds gives a mean cycle difference of
1.07 (± 0.32 SD) with 95% confidence limits of +0.97&
+1.17. A mouse homozygous for Wlds gives mean cycle
difference of 2.07 (± 0.30 SD) with 95% confidence limits
of +01.995 & +2.158 (Figure 4).
Plotting the ∆Ct against animals of known genotype in a
box and whisker plot (N = 36) allows the illustration of
95% confidence limits for each genotype (Figure 4).
When plotting a scatter of the results for all of the animals
of unknown genotype (N = 91) there was a clear banding
into the 3 genotypes as demonstrated by the box and
whisker plot of animals of known genotype (Figure 4).
Only one sample fell outwith the 95% confidence limits
for all of the plotted genotypes shown (Figure 4). In such
circumstances, the genotyping for this particular sample
should be considered invalid. The Wlds status of a repre-
sentative set of unknown genotype animals whose iden-
tity was determined by QPCR was successfully confirmed
using breeding records, Southern blotting techniques and
subsequent experiments where the neuroprotective phe-
notype was revealed by nerve lesion and the use of mor-
phological techniques (data not shown).
Determining copy number in transgenic animals
Transgenic animals (mice and rats) have been generated
which express the Wlds chimeric gene [13,18]. These ani-
mals show a strong neuroprotective phenotype. As it has
QPCR on genomic DNA shows clear difference in ∆Ct for  the 3 genotypes Figure 4
QPCR on genomic DNA shows clear difference in 
∆Ct for the 3 genotypes. A graphical representation of 
∆Ct between the tubulin and Wld amplicons, for animals of 
known genotype (N = 36, box and whisker) and animals of 
unknown genotype (N = 91, scatter). The areas shown in 
blue represent the 95% confidence limits for each particular 
genotype as determined from the box and whisker plots. 
There is a clear trend for each particular genotype.
Real time data shows differences between wild-type, hetero- zygous and homozygous animals Figure 3
Real time data shows differences between wild-type, 
heterozygous and homozygous animals. Screen grabs 
from ABI software. The curves show the difference in cycle 
number (∆Ct) between tubulin (pseudo-coloured red) and 
Wlds (pseudo-coloured green) for each genotype at the set 
threshold (1.0e+000, pseudo-coloured blue). These are rep-
resentative curves only and should be viewed in conjunction 
with Figure 4.Molecular Neurodegeneration 2007, 2:21 http://www.molecularneurodegeneration.com/content/2/1/21
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previously been shown that the Wlds neuroprotective phe-
notype is dose-dependent (see above), it is therefore of
interest to determine the number of copies which have
been integrated into the genome of these transgenic ani-
mals.
We examined 2 rat models of Wlds: the transgenic line 23
and transgenic line 79 [13]. Through the use of QPCR on
genomic DNA (utilising the 2-∆∆CT  method described
above) it is possible to calculate the copy number of inser-
tions into the rat genome. The results examining the
number of inserts in two of the Wlds transgenic lines can
be seen in Figure 5. There was additional variability in the
amplification process at higher copy number with QPCR,
as previously described when using this technology [22].
However, the data show that transgenic rat lines 23 and 79
contain 12.34 ± 2.05 (N = 10) and 19.49 ± 1.52 (N = 14)
copies of the Wlds gene respectively, significantly more
than homozygous Wlds mice, as would be expected in
transgenic animals generated using non-targeted inser-
tion. It is also important to note that the data do not give
any indication of transgene orientation or functionality.
Despite this, the increase Wlds copy number in the trans-
genic rats tallies with previously reported increases in phe-
notypic strength compared to homozygous Wlds  mice
[13].
It is especially important to measure WldS copy number
and expression level before making conclusions about its
effects when attempting to transfer protective benefits to
models of disease. For instance, two reports suggest little
or no mitigation of disease onset or progression after
crossbreeding WldS mice with mouse models of amyo-
trophic lateral sclerosis (8,15); but it is presently unclear
whether these reports fully accounted for the known,
weak synaptic-protective effects of the WldS gene in heter-
ozygous and aged mice (3,18).
Conclusion
The QPCR genotyping method we report here facilitates
accurate, rapid and effective genotyping of Wlds  copy
number in both spontaneous mutant mice and transgenic
animals expressing Wlds, representing an improved, cost
effective and more efficient general purpose method than
PFGE, the most accurate alternative method reported thus
far. This methodology should be of interest to groups
working on other mutations which are difficult to geno-
type as the DNA does not need to be accurately quantified
before use. This is because the methodology works by
examining ratios between PCR product of interest and
controls rather than absolute levels. It is also applicable to
smaller tissue samples such as ear punches. This tech-
nique will be of particular benefit for current and future
studies where Wlds mice or their transgenic equivalents,
are being crossed with other strains, and especially rele-
vant for studies attempting to understand the relationship
between gene-dosage of the Wlds mutation and the effec-
tiveness of its neuroprotective phenotype.
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QPCR can be used to determine copy number in transgenic  animals Figure 5
QPCR can be used to determine copy number in 
transgenic animals. QPCR carried out on samples of 
genomic DNA can be used to determine copy number of an 
insert in rat transgenic lines (Tg) 23 and 79. Although there is 
some fluctuation in the determined copy number, wild-type 
(WT) animals are expected to have 2 copies. Heterozygous 
Wlds (Het-Wld) are expected to have 4 copies and 
homozygous Wlds (Hom-Wld) should have 6 copies. Analysis 
of the QPCR data showed the following copy numbers: WT 
1.15 ± 0.68 (mean ± SEM) copies (N = 13), Het-Wld 3.87 ± 
0.36 copies (N = 7), Hom-Wld 6.10 ± 0.53 copies (N = 7), 
Tg23 12.34 ± 2.05 (N = 10) and Tg79 19.49 ± 1.52 (N = 14).Publish with BioMed Central    and   every 
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